INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 132 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2016. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $6,426,663 | +123.7% | 101,495 | +84.9% | 0.23% | +48.1% |
Q4 2021 | $2,873,000 | +212.6% | 54,885 | +122.7% | 0.16% | +243.5% |
Q3 2021 | $919,000 | -66.0% | 24,642 | -62.8% | 0.05% | -56.2% |
Q2 2021 | $2,704,000 | -38.7% | 66,232 | -49.1% | 0.10% | -26.1% |
Q1 2021 | $4,412,000 | -29.3% | 130,032 | -33.7% | 0.14% | -55.2% |
Q4 2020 | $6,237,000 | +116.0% | 196,126 | +74.3% | 0.32% | +77.1% |
Q2 2020 | $2,888,000 | +456.5% | 112,500 | +181.2% | 0.18% | +397.2% |
Q2 2019 | $519,000 | -59.0% | 40,000 | -61.5% | 0.04% | -49.3% |
Q1 2019 | $1,267,000 | -79.7% | 104,000 | -75.9% | 0.07% | -78.4% |
Q4 2017 | $6,253,000 | +42.3% | 431,874 | +55.1% | 0.33% | +48.4% |
Q3 2017 | $4,393,000 | +320.0% | 278,400 | +230.6% | 0.22% | +287.7% |
Q2 2017 | $1,046,000 | +37.3% | 84,200 | +68.4% | 0.06% | +29.5% |
Q3 2016 | $762,000 | – | 50,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |